Mid-Stage HIV Vaccine Trial Shows Encouraging Results
Posted on: Thursday, 23 August 2007, 12:13 CDT
A HIV vaccine developed by the National Institutes of Health induced T-cell immune responses in up to 70% of the vaccine recipients in a Phase IIa trial, according to manufacturer Vical.
The trials involved priming an immune response with three doses of a plasmid DNA (pDNA) vaccine over a two-month period, based on Vical's proprietary DNA technology, and boosting the response with a single dose of adenoviral vector vaccine at six months.
"These recent vaccine trials contribute to the growing body of knowledge demonstrating plasmid DNA priming as a key factor in achieving significant immune responses against HIV, a particularly difficult target pathogen, bringing us one step closer to evaluating the effectiveness of a prime-boost HIV vaccine regimen in a prophylactic setting," said Vijay Samant, Vical's president and CEO.
Source: Datamonitor
Related Articles
- GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
- Inovio Biomedical Achieves 75% Complete Response Rate in Preclinical Testing of DNA-Based Cancer Vaccine Using Its Electroporation DNA Delivery System
- Inovio Biomedical Expands In Vivo Electroporation License With International AIDS Vaccine Initiative for HIV Vaccine Research
- VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
- Nasal Vaccines Produce Immunity Against Smallpox, HIV
- Inovio Biomedical Highlights Enhanced DNA Vaccine Potency With Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
- CytoGenix DNA Vaccine Successful Against HIV
- Single Injection of Vical's Avian Flu DNA Vaccine Provides 100% Protection in Ferrets
- Dynavax's Flu Vaccine Shows Immunity to Divergent and Potentially Pandemic Flu Strains in Preclinical Tests
- Development of Therapeutic, Prevention Vaccines in Progress: HIV Co- Discoverer
 |
 |
User Comments (0)
RSS Feeds